Nxera Pharma Reports Revenue Growth Amid Net Loss

Sosei Group Corporation ( (SOLTF) ) has released its Q2 earnings. Here is a breakdown of the information Sosei Group Corporation presented to its investors.

Nxera Pharma Co., Ltd is a biopharmaceutical company listed on the Tokyo Stock Exchange, specializing in drug discovery and development, with operations spanning from the UK to Japan and South Korea, and a focus on G Protein-Coupled Receptors (GPCRs).

In the first half of 2025, Nxera Pharma reported an 18.7% increase in revenue compared to the same period last year, reaching JPY 15,094 million. Despite this growth, the company experienced a net loss of JPY 3,137 million, which is an improvement from the JPY 4,703 million loss in the previous year.

Key financial highlights include the company’s revenue growth driven by marketed products such as PIVLAZ® and QUVIVIQ®, and increased milestone revenue from research and development collaborations. However, the core operating profit decreased significantly due to higher research and development expenses and a decrease in selling, general, and administrative expenses.

Strategically, Nxera Pharma is focusing on expanding its drug pipeline, particularly in obesity and metabolic disorders, and enhancing its NxWave™ platform technology. The company has also entered into new agreements to advance its clinical programs in Japan and the APAC region.

Looking ahead, Nxera Pharma aims to continue its strategic growth by leveraging partnerships and advancing its drug programs, while maintaining a focus on delivering innovative medicines to patients in Japan and the broader APAC region.